ECO Animal Health Group pleased with recent trading

ECO Animal Health
[shareaholic app="share_buttons" id_name="post_below_content"]

ECO Animal Health Group plc (LON:EAH), a leader in the development, registration and marketing of pharmaceutical products for global animal health markets has provided an unaudited trading update for the financial year ending 31st March 2022.

ECO commented in early January 2022 that China pork prices were volatile, and producers remained cautious. Although these trading conditions have persisted throughout the first quarter of 2022, ECO has continued to trade in line with revised revenue and margin expectations.

Further encouraging progress has been made within the R&D portfolio and investment was maintained at the budgeted rate, resulting in R&D cash expenditure, including capitalisation, of about 13% of revenue in the full year and a charge to the income statement of £8.7million.  This charge to the income statement reflects some exciting early-stage technologies. This, together with further investment in critical support functions, is expected to result in EBITDA (for the year ending 31 March 2022) 15% to 20% below consensus expectations.

Exposure to Russia and Ukraine

The ECO Group has no business in Ukraine. The annual revenue derived from Russia has been less than £0.5m in each of the last three financial years. The current receivables due from the ECO distributor in Russia are approximately €430,000 and the Board continues to explore a number of mechanisms to recover this debt.

Marc Loomes, ECO Animal Health CEO said:

“The pork commodity price in China continues to be volatile but we are pleased with recent trading and our expectation of meeting revenue consensus is an important indicator of a return to more stable trading conditions. We have kept investment on critical organisation development and strategic R&D at our planned levels despite the reduced revenues from China. This decision is beginning to bear fruit and we look forward with excitement to the announcement of new regulatory approvals.”

“We hope for a speedy resolution to the conflict in Ukraine and stay ready to support our business partners in Eastern Europe in any way we can.” 

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
ECO Animal Health Group plc has announced the disposal of ECOmectin® Horsepaste to ACME Drugs S.r.l in Italy, focusing on core species of pigs and poultry.
ECO Animal Health Group plc (LON:EAH) updates on trading and business progress, with strong revenue driven by Aivlosin® and R&D investments for future growth.
ECO Animal Health Group plc has appointed Dr. Joachim Hasenmaier as a Non-Executive Director. With extensive experience in the animal health industry, Dr. Hasenmaier's appointment is expected to drive growth and capitalize on future opportunities.
ECO Animal Health Group plc has announced that its trademark, ECOVAXXIN®, has been approved by the European Union, providing extensive protection in key markets for animal health products. This trademark will brand a family of vaccine products, supporting the company's strategy of growth through R&D.

Search

Search